A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

[1]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[2]  B. Griffith,et al.  Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. , 1994, The Journal of thoracic and cardiovascular surgery.

[3]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[4]  P. Macchiarini,et al.  Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. , 1993, The Journal of thoracic and cardiovascular surgery.

[5]  J. Mcewen.  The Nottingham Health Profile , 1993 .

[6]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[7]  J. Darbinian,et al.  Complications of home parenteral nutrition. , 1992, Clinical pharmacy.

[8]  M. Pasque,et al.  Single‐Lung Transplantation for Pulmonary Hypertension: Three‐Month Hemodynamic Follow‐up , 1991, Circulation.

[9]  D. Graham,et al.  Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. , 1991, The American journal of medicine.

[10]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[11]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[12]  A. Feinstein,et al.  Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. , 1989, The American journal of cardiology.

[13]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[14]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[15]  E. Robin,et al.  PRIMARY PULMONARY HYPERTENSION , 2022 .

[16]  B. Groves,et al.  The case for treatment of selected patients with primary pulmonary hypertension. , 1986, The American review of respiratory disease.

[17]  R. Barst.  Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. , 1986, Chest.

[18]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[19]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[20]  G. Bàlint,et al.  Cytoprotective effect of prostacyclin and protein synthesis. , 1983, Acta physiologica Hungarica.

[21]  B. Groves,et al.  Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.

[22]  S. Hunt,et al.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. , 1982, The New England journal of medicine.

[23]  A. Dembińska-kieć,et al.  Role of mucosal prostaglandins and DNA synthesis in gastric cytoprotection by luminal epidermal growth factor. , 1981, Gut.

[24]  B. Molony,et al.  Intravenous Infusion of Prostacyclin Sodium in Man: Clinical Effects and Influence on Platelet Adenosine Diphosphate Sensitivity and Adenosine 3′:5′‐Cyclic Monophosphate Levels , 1981, Circulation.

[25]  P. Kadowitz,et al.  Pulmonary Vasodilator Activity of Prostacyclin (PGI2) in the Cat , 1979, Circulation research.

[26]  R. L. Elliott,et al.  Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI2). , 1979, Prostaglandins and medicine.

[27]  A. M. Lefer,et al.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. , 1978, Science.

[28]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[29]  Dana Quade,et al.  Rank Analysis of Covariance , 1967 .

[30]  J. L. Hodges,et al.  Estimates of Location Based on Rank Tests , 1963 .

[31]  D. Dresdale,et al.  Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.

[32]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .